Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Erlotinib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR known ✓ | P00533 | 15/20 | 1.00 |
| ▸ | ERBB2 | P04626 | 4/20 | 1.00 |
| ▸ | GAK | O14976 | 3/20 | 0.98 |
| ▸ | ILK | Q13418 | 3/20 | 0.98 |
| ▸ | FLT1 | P17948 | 2/20 | 0.98 |
| ▸ | KDR | P35968 | 2/20 | 0.98 |
| ▸ | PLK4 | O00444 | 1/20 | 0.98 |
| ▸ | CIT | O14578 | 1/20 | 0.98 |
| ▸ | AURKA | O14965 | 1/20 | 0.98 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.98 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.98 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.98 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.98 |
| ▸ | BUB1 | O43683 | 1/20 | 0.98 |
| ▸ | KDM1A | O60341 | 1/20 | 0.98 |
| ▸ | JAK2 | O60674 | 1/20 | 0.98 |
| ▸ | RPS6KA4 | O75676 | 1/20 | 0.98 |
| ▸ | STK17B | O94768 | 1/20 | 0.98 |
| ▸ | STK10 | O94804 | 1/20 | 0.98 |
| ▸ | SLCO2B1 | O94956 | 1/20 | 0.98 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Erlotinib SCHEMBL21176918 | 1.00 | EGFR (1.00) | EGFRERBB2GAKILKFLT1 | |
| Erlotinib SCHEMBL16767632 | 1.00 | EGFR (1.00) | EGFRERBB2GAKILKFLT1 | |
| Erlotinib SCHEMBL29460839 | 1.00 | EGFR (1.00) | EGFRERBB2GAKILKFLT1 | |
| Erlotinib SCHEMBL3826918 | 0.99 | EGFR (0.98) | EGFRERBB2GAKILKFLT1 | |
| Erlotinib SCHEMBL1759094 | 0.99 | EGFR (0.98) | EGFRERBB2GAKILKFLT1 | |
| Erlotinib SCHEMBL29351329 | 0.99 | EGFR (1.00) | EGFRERBB2GAKILKFLT1 | |
| Erlotinib SCHEMBL30362833 | 0.99 | EGFR (1.00) | EGFRERBB2GAKILKFLT1 | |
| Erlotinib SCHEMBL8413 | 0.99 | EGFR (1.00) | EGFRERBB2GAKILKFLT1 | |
| Erlotinib SCHEMBL3667407 | 0.99 | EGFR (1.00) | EGFRERBB2GAKILKFLT1 | |
| Erlotinib SCHEMBL1959332 | 0.98 | EGFR (0.98) | EGFRERBB2GAKILKFLT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 7102 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116162546-B | Drug screening tumor organoid chip and drug screening method | DALIAN INSTITUTE OF CHEMICAL PHYSICS, CHINESE ACADEMY OF SCIENCES (CN) | 2026-05-26 | — | — | CN | claimed |
| US-20260132141-A1 | PROTEIN PHOSPHATASE 2A ACTIVATORS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2026-05-14 | — | — | US | claimed |
| US-20260097049-A1 | CANNABINOID ANALOGS AND METHODS OF USE FOR TREATMENT AND PREVENTION OF CANCER | BLACKSTONE THERAPEUTICS, LLC (US) | 2026-04-09 | — | — | US | claimed |
| EP-4709378-A1 | COMPOUNDS FOR NOS-RELATED CANCERS AND METHODS OF USE | Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. (IL) | 2026-03-18 | — | — | EP | claimed |
| US-20260069700-A1 | BRUSH PRODRUGS AND USES THEREOF | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2026-03-12 | — | — | US | claimed |
| US-20250367201-A1 | COMBINATION THERAPY FOR TREATING ABNORMAL CELL GROWTH | VERASTEM INC (US) | 2025-12-04 | — | — | US | claimed |
| US-12478683-B2 | Brush prodrugs and uses thereof | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2025-11-25 | — | — | US | claimed |
| US-20250332253-A1 | METHODS FOR TREATING TUMORS | RENOVORX INC (US) | 2025-10-30 | — | — | US | claimed |
| EP-4593963-A1 | CANNABINOID ANALOGS AND METHODS OF USE FOR TREATMENT AND PREVENTION OF CANCER | Blackstone Therapeutics, LLC (US) | 2025-08-06 | — | — | EP | claimed |
| US-20250242046-A1 | ALLOGENEIC HYPOIMMUNE BIOMIMETIC NANOVESICLE FOR THE TREATMENT OF CANCER | MALCOLM THOMAS (US) | 2025-07-31 | — | — | US | claimed |
| EP-1597239-A1 | POLYMORPH OF {6,7-BIS(2-METHOXY-ETHOXY)-QUINAZOLIN-4-YL}-(3E) | F. HOFFMANN-LA ROCHE AG (CH) | 2005-11-23 | — | — | EP | claimed |
| US-6900221-B1 | Stable polymorph on N-(3-ethynylphenyl)-6, 7-bis (2methoxyethoxy)-4-quinazolinamine hydrochloride, methods of production, and pharmaceutical uses thereof | OSI PHARMACEUTICALS, INC. (US) | 2005-05-31 | — | — | US | claimed |
| WO-2005037259-A2 | METHODS AND COMPOSITIONS FOR THE PREVENTION OR TREATMENT OF NEOPLASIA COMPRISING A COX-2 INHIBITOR IN COMBINATION WITH AN EPIDERMAL GROWTH FACTOR RECEPTOR ANTAGONIST | PHARMACIA CORPORATION (US) | 2005-04-28 | — | — | WO | claimed |
| WO-2004072049-A1 | POLYMORPH OF {6,7-BIS(2-METHOXY-ETHOXY)-QUINAZOLIN-4-YL}-(3E) | F. HOFFMANN-LA ROCHE AG (CH) | 2004-08-26 | — | — | WO | claimed |
| US-20040162300-A1 | Novel [6,7-Bis(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)amine hydrochloride polymorph | F. HOFFMANN-LA ROCHE AG (CH) | 2004-08-19 | — | — | US | claimed |
| US-20040138140-A1 | Combination cancer therapy with a GST-activated anticancer compound and another anticancer therapy | TELIK, INC. | 2004-07-15 | — | — | US | claimed |
| EP-1420747-A2 | BENZOQUINONE ANSAMYCINS | Kosan Biosciences, Inc. (US) | 2004-05-26 | — | — | EP | claimed |
| US-20030114450-A1 | Anticancer agents; antiproliferative agent | KOSAN BIOSCIENCES, INC. | 2003-06-19 | — | — | US | claimed |
| WO-2003013430-A2 | BENZOQUINONE ANSAMYCINS | KOSAN BIOSCIENCES, INC. (US) | 2003-02-20 | — | — | WO | claimed |
| EP-0817775-B1 | QUINAZOLINE DERIVATIVES | PFIZER (US) | 2001-09-12 | — | — | EP | claimed |